Author: Buonaguro, Franco Maria; Puzanov, Igor; Ascierto, Paolo Antonio
Title: Anti-IL6R role in treatment of COVID-19-related ARDS Document date: 2020_4_14
ID: 0pigqtzt_10
Snippet: The clinical presentation of patients with severe forms of COVID-19 resembles cytokine release syndrome (CRS) observed in some oncology patients treated with CAR-T cell therapies. There, IL-6R inhibition with tocilizumab (anti-IL-6R antibody) proved effective and was FDA approved in 2017. IL-6 and its receptor signaling were shown to play a role in immune response to H1N1 influenza and prevention of lung damage [3] [4] [5] . However, administrati.....
Document: The clinical presentation of patients with severe forms of COVID-19 resembles cytokine release syndrome (CRS) observed in some oncology patients treated with CAR-T cell therapies. There, IL-6R inhibition with tocilizumab (anti-IL-6R antibody) proved effective and was FDA approved in 2017. IL-6 and its receptor signaling were shown to play a role in immune response to H1N1 influenza and prevention of lung damage [3] [4] [5] . However, administration of tocilizumab has not prevented influenza vaccination immune response in patients with rheumatoid arthritis [6] . its role in patients infected with SARS-CoV-2 has not yet been fully studied and is awaiting completion of clinical trials under way.
Search related documents:
Co phrase search for related documents- anti tocilizumab antibody and clinical trial: 1, 2, 3
- anti tocilizumab antibody and CRS cytokine release syndrome: 1
- anti tocilizumab antibody and cytokine release: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- anti tocilizumab antibody and cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
- anti tocilizumab antibody and H1N1 influenza: 1
- anti tocilizumab antibody and immune response: 1, 2, 3
- anti tocilizumab antibody and immune response role: 1
- anti tocilizumab antibody and lung damage: 1, 2
- anti tocilizumab antibody and receptor signaling: 1, 2
- anti tocilizumab antibody and tocilizumab administration: 1, 2, 3, 4, 5, 6
- cell therapy and clinical presentation: 1, 2, 3, 4, 5, 6
- cell therapy and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- cell therapy and CRS cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- cell therapy and cytokine release: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- cell therapy and cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- cell therapy and H1N1 influenza: 1
- cell therapy and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cell therapy and immune response role: 1, 2
- cell therapy and influenza vaccination: 1, 2
Co phrase search for related documents, hyperlinks ordered by date